Objective： To investigate the expressions of p53, RB1, Fas, c-fos, Ras, EGFR mRNA in human cervical cancer （HeLa） cell in response to the trichostatin A （TSA）. Methods： We took count of HeLa cells in different i...Objective： To investigate the expressions of p53, RB1, Fas, c-fos, Ras, EGFR mRNA in human cervical cancer （HeLa） cell in response to the trichostatin A （TSA）. Methods： We took count of HeLa cells in different incubation times with TSA （0.2μm/L）. The result indicated that HeLa cells changed evidently when HeLa cells were incubated for 36 h. Then, we investigated the genes expression （mRNA levels） of HeLa cells after treatment for 36 h using SYBR green real-time PCR. Results： We demonstrated that trichostatin A （TSA） could make human cervical cancer （HeLa） cell morphological change and induce HeLa cell apoptosis. Furthermore, the data suggest that TSA-induced down-regulation of p53, RB1, Fas, but upregulated c-fos gene expression after treatment for 36 h, and Ras, EGFR did not show obvious response to TSA treatments. Conclusion： TSA has different effects on gene expression.展开更多
背景与目的:腺病毒感染依赖于靶细胞表面柯萨奇-腺病毒受体(Coxsackie and adenovirus receptor,CAR)的表达,肿瘤细胞CAR表达的缺失和下调是造成腺病毒为载体基因治疗效果不佳的根本原因。本研究通过观察组氨酸去乙酰化酶(histone deace...背景与目的:腺病毒感染依赖于靶细胞表面柯萨奇-腺病毒受体(Coxsackie and adenovirus receptor,CAR)的表达,肿瘤细胞CAR表达的缺失和下调是造成腺病毒为载体基因治疗效果不佳的根本原因。本研究通过观察组氨酸去乙酰化酶(histone deacetylase,HDAC)抑制剂TrichostatinA(TSA)对卵巢癌细胞株A2780CAR表达水平的影响,探讨HDAC抑制剂在腺病毒载体基因治疗中应用的可能性。方法:分别在TSA作用A2780细胞前后检测CARmRNA和蛋白水平的表达,同时采用流式细胞术测定病毒转染效率,MTT实验评价腺病毒携带的胸苷激酶(ADV/TK)的体外抗瘤效应。结果:TSA处理后,A2780细胞内CARmRNA和蛋白表达明显增高。通过流式细胞仪分析GFP/ADV转染后GFP的表达发现,未处理组细胞转染率为(1.24±0.14)%;5nmol/L和100nmol/LTSA处理48h后,细胞的转染效率分别为(7.58±0.32)%和(7.94±0.28)%。MTT结果表明,ADV/TK介导的体外杀伤作用在5nmol/L和100nmol/LTSA处理组较未处理组增强了4～10倍。结论:TSA可以增强针对卵巢癌细胞的腺病毒基因转染效率,为增强卵巢癌基因治疗效果提供可能的方法。展开更多
基金a grant from the National Science and Technique Foundation during the Tenth Five-Year Plan Period of China(No.2001BA302B-03)
文摘Objective： To investigate the expressions of p53, RB1, Fas, c-fos, Ras, EGFR mRNA in human cervical cancer （HeLa） cell in response to the trichostatin A （TSA）. Methods： We took count of HeLa cells in different incubation times with TSA （0.2μm/L）. The result indicated that HeLa cells changed evidently when HeLa cells were incubated for 36 h. Then, we investigated the genes expression （mRNA levels） of HeLa cells after treatment for 36 h using SYBR green real-time PCR. Results： We demonstrated that trichostatin A （TSA） could make human cervical cancer （HeLa） cell morphological change and induce HeLa cell apoptosis. Furthermore, the data suggest that TSA-induced down-regulation of p53, RB1, Fas, but upregulated c-fos gene expression after treatment for 36 h, and Ras, EGFR did not show obvious response to TSA treatments. Conclusion： TSA has different effects on gene expression.
文摘背景与目的:腺病毒感染依赖于靶细胞表面柯萨奇-腺病毒受体(Coxsackie and adenovirus receptor,CAR)的表达,肿瘤细胞CAR表达的缺失和下调是造成腺病毒为载体基因治疗效果不佳的根本原因。本研究通过观察组氨酸去乙酰化酶(histone deacetylase,HDAC)抑制剂TrichostatinA(TSA)对卵巢癌细胞株A2780CAR表达水平的影响,探讨HDAC抑制剂在腺病毒载体基因治疗中应用的可能性。方法:分别在TSA作用A2780细胞前后检测CARmRNA和蛋白水平的表达,同时采用流式细胞术测定病毒转染效率,MTT实验评价腺病毒携带的胸苷激酶(ADV/TK)的体外抗瘤效应。结果:TSA处理后,A2780细胞内CARmRNA和蛋白表达明显增高。通过流式细胞仪分析GFP/ADV转染后GFP的表达发现,未处理组细胞转染率为(1.24±0.14)%;5nmol/L和100nmol/LTSA处理48h后,细胞的转染效率分别为(7.58±0.32)%和(7.94±0.28)%。MTT结果表明,ADV/TK介导的体外杀伤作用在5nmol/L和100nmol/LTSA处理组较未处理组增强了4～10倍。结论:TSA可以增强针对卵巢癌细胞的腺病毒基因转染效率,为增强卵巢癌基因治疗效果提供可能的方法。
